To assess the occurrence of 3 major adverse outcomes of sarcopenia (ie, physical disabilities, institutionalizations and deaths) observed over a 3-year follow-up in older adults and compare the risk of these outcomes using 5 definitions of sarcopenia.
We aimed to quantify the increased risk of disability associated with cardiovascular risk factors among older adults, and to verify whether this risk may vary by age and functional status.
To investigate the effect of low-dose statins and apolipoprotein E () genotypes on cerebral small vessel disease (CSVD) to prevent CSVD in older hypertensive patients.